1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 13,30€ (+15,75%). The median is 13,30€ (+15,75%).
| Buy |
4 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0.00 | - |
| Gross profit | −26.47k | - |
| Net profit | −40.84m | 95,60% |
| EBITDA | −41.89m | 100,83% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 692.56m€ |
Number of shares | 61.98m |
52-week high/low | 11,36€ - 3,23€ |
| Dividends | No |
Beta | 0,56 |
P/E ratio | −3,11 |
PEG ratio | −0,14 |
P/B ratio | 2,83 |
P/S ratio | 0,00 |
Company profile
| Name | Cybin |
| CEO | Michael Halstead |
| Headquarters | Toronto,
on Canada |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Employees | 100 |
Discover assets
Shareholders of Cybin also invest in the following assets
